ARTICLE | Company News
Europe approves Amgen's Aranesp
June 11, 2001 7:00 AM UTC
Europe granted marketing approval to AMGN for its Aranesp modified erythropoietin to treat anemia in patients with chronic renal failure. Aranesp is to be dosed once a week or once every two weeks. AMGN's first generation Epogen recombinant erythropoietin is given three times a week. ...